← Taiwan Stock Snapshot Database

Home / Indicator library / Biotechnology and Medical Care / Handa Pharma (6620) overview

Handa Pharma (6620) stock overview

Valuation, financials, growth, ownership, events, dividends, models and adjusted prices for Handa Pharma, on one page

中文版 (Chinese)

Handa Pharma (6620) snapshot, key figures

Price / earnings
51.74x
Price / book
—
Dividend yield
1.39%
Revenue YoY (2026-08)
-79.9%
Monthly revenue (2026-08)
TWD 0.07bn
Sector
Biotechnology and Medical Care
Values above are the official-source snapshot for Handa Pharma (6620) on 2026-09-17. We do not chase live quotes. Every trading day is frozen as its own point-in-time vintage, so a backtest reading this data sees only what was actually knowable that day, with no look-ahead bias. Missing values stay blank. Nothing is interpolated or extrapolated.

Handa Pharma (6620): where today sits in the past year

Current value against the 2025-09-17 to 2026-09-17 range, built from 179 frozen daily vintages.

Price / earnings51.74x100th percentile of the past year
13.92xmedian 18.56x51.04x
Dividend yield1.39%0th percentile of the past year
1.41%median 2.41%2.96%
The marker is today's value; the faint tick is the one-year median. Every point in this range is the number as it was published on its own date, never a restated figure, so the percentile is what a reader on that day could actually have computed. Ratios at or below zero are excluded rather than treated as cheap. Tickers with fewer than 60 observed dates get no range at all.
That is this ticker against its own past. The other axis — where the same readings sit across the whole market on the same day — is directly below; the two can point in different directions, so both are worth reading. The full decile structure lives on the market P/E, P/B and dividend yield pages.

Handa Pharma (6620): where today sits across the whole market

The same figures read against every other listed company on 2026-09-17, rather than against this ticker's own history.

Price / earnings51.74x85th percentile market-wide
10th pct9.01xmarket median18.04x90th pct69.79x
Dividend yield1.39%34th percentile market-wide
10th pct0.00%market median2.69%90th pct6.74%
Valid sample per metric: price / earnings 1,542, dividend yield 1,734. The three metrics are sampled independently rather than intersected, so the denominators differ — an intersection would turn every percentile into the percentile of whichever companies happen to disclose all three, a population nobody is asking about. Ratios at or below zero are excluded rather than counted as cheap; a zero dividend yield is kept because paying nothing is a real observation. The bar spans the 10th to 90th percentile, not the full range, because a handful of four-digit multiples would otherwise flatten every other company into the left edge; the percentile itself is computed on the full population and is unaffected.
The full decile structure behind these percentiles is on the market P/E, P/B and dividend yield distribution pages.
Checkup signals: 3 green / 1 amber / 3 red Full checkup →
Financial quality (F-score)Valuation percentile (P/E vs market)Revenue momentum (latest month, YoY)Ownership concentration (1,000-lot holders, weekly)Insider pledge ratioInsider disposal filings (last 60 days)Buyback announcements (last 12 months)

Seven-dimension checkup for this ticker →

Valuation river

→
P/E 51.74x · market rank 85th percentile across the market

Financial quality

→
F-score quality checks passed: 1 of 2 checks that could be computed

Revenue growth

→
Monthly revenue, 2026-08: -79.9% year on year

Ownership structure

→
Large holders at 49.59%, -0.09 points week on week · insider pledge 0.0% as of 2026-08-31

Events, last 90 days

→
Loading…

Yield river

→
Cash dividend yield in the latest snapshot: 1.39%

Valuation models

→
Loading…

Adjusted-price candles

→
Loading…

6620: common questions

What is 6620's P/E ratio?

6620 traded at a price-to-earnings ratio of 51.74x in the official-source snapshot dated 2026-09-17. That figure is frozen as a point-in-time vintage, so a backtest reading it sees only what was knowable that day.

What is 6620's dividend yield?

6620's cash dividend yield was 1.39% on 2026-09-17. Historical dividend policy and gap-fill records are available on the same page.

How fast is 6620's revenue growing?

6620 reported -79.9% year-on-year monthly revenue growth for 2026-08, from the official monthly revenue filing.

Is 6620's price / earnings high or low right now?

6620's price / earnings is 51.74x, which is above its one-year median of 18.56x and sits at the 100th percentile of the 13.92–51.04x range observed over the last 179 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.

Is 6620's dividend yield high or low right now?

6620's dividend yield is 1.39%, which is below its one-year median of 2.41% and sits at the 0th percentile of the 1.41–2.96% range observed over the last 179 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.

How does 6620's price / earnings compare with the rest of the Taiwan market?

6620's price / earnings of 51.74x is above the market median of 18.04x and sits at the 85th percentile of the 1,542 tickers carrying a valid reading that day — 226 of them read higher. This is the cross-section on a single frozen date, a different question from where the ticker sits against its own past year.

How does 6620's dividend yield compare with the rest of the Taiwan market?

6620's dividend yield of 1.39% is below the market median of 2.69% and sits at the 34th percentile of the 1,734 tickers carrying a valid reading that day — 1,146 of them read higher. This is the cross-section on a single frozen date, a different question from where the ticker sits against its own past year.

Other Biotechnology and Medical Care tickers

159 Taiwan-listed tickers sit in this sector. See the full Biotechnology and Medical Care table.

Everything on this page is either the official public source shown as-is, or a transparent derivation you can reproduce. The free tier covers 2330 in full as a reference case; on other tickers some blocks are paid-tier. What we sell is data and tooling, not investment advice, not stock tips, and not a promise of returns.